Classified in the pharmaceuticals sector, the company reported nil revenue from operations in FY26 with total income of Rs 86.45 lakhs. The Board has acknowledged that post-Covid business impact continues, particularly affecting operations that require personal relationships, alongside a shrinking regular customer base. The company recorded a loss before exceptional items of Rs 64.85 lakhs in FY26, but reported a net profit of Rs 797.07 lakhs driven by an exceptional gain of Rs 1,116.65 lakhs from the sale of immovable properties and investment properties in Maharashtra, which had a written-down value of Rs 56.92 lakhs and were sold for approximately Rs 1,173.20 lakhs in cash. The company carries no outstanding loans or financial indebtedness, and operating cash flow was negative Rs 287.40 lakhs in FY26. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Pharmaceutical operations. Pharmaceutical company with no operating revenue in FY26, debt-free, reliant on asset sale gains for profitability
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 9 | 0 | 0 | 0 | 0 |
| EBITDA (ex other income) | 1 | (1) | (2) | (1) | 10 |
| margin % | 15.1 | — | — | — | — |
| Owners' profit | 1 | (1) | (1) | (0) | 8 |
| EPS, as reported (₹) | 53.99 | (36.13) | (41.36) | 16.33 | 325.34 |
| ROE % · ROCE % | 10.1 · 13.6 | (7.6) · (10.1) | (6.9) · (9.1) | (2.9) · (1.8) | 38.6 · 50.8 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 3 | (2) | (4) | 0 | (3) |
| Capex | (0) | 0 | 0 | 0 | 0 |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | (0) | (0) | (0) | (0) | (0) | (0) | (0) | 11 |
| Net profit | (0) | (0) | 0 | (0) | (0) | (0) | (0) | 8 |
| EPS (₹) | (3.20) | (1.49) | 3.60 | 18.44 | 1.25 | 7.86 | 5.38 | 339.83 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 24 Aug 2026 · Triochem Products submits FY26 Annual Report approved at AGM | compliance | low | — | — |
| 24 Aug 2026 · Triochem Products AGM: All 3 resolutions passed with 100% approval | board shareholder meetings | low | — | — |
| 22 Aug 2026 · Triochem Products 54th AGM: key resolutions passed, Rs 1,116 lakh gain from asset sale | board shareholder meetings | low | — | — |
| 19 Aug 2026 · Newspaper Publication of Q1 FY27 Unaudited Results | compliance | minimal | — | — |
| 14 Aug 2026 · Fund use deviation statement not applicable for Q1 FY27 | compliance | minimal | — | — |
| 14 Aug 2026 · Triochem Q1 FY27 PAT at Rs 9.48L; revenue down 25% YoY | results | high | — | — |
| 14 Aug 2026 · Q1 FY27 results: revenue declines, profit at Rs 9.48 lakh | results | medium | — | — |
| 10 Aug 2026 · Notice of board meeting on 14 August 2026 | compliance | minimal | — | — |
| 8 Aug 2026 · Board meeting on 14 Aug 2026 to consider Q1 FY27 results | results | low | — | — |
| 31 Jul 2026 · Notice of 54th AGM published in newspaper | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| ROCE | 50.5 | 10.8 | 4 of 183 | 98% |
| ROE | 38.6 | 10.4 | 11 of 171 | 94% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| Profit growth | 1942.8 | 30.9 | 4 of 158 | 98% |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
